In vitro evaluation of dinactin, a potent microbial metabolite against Mycobacterium tuberculosis

Tuberculosis (TB), caused by Mycobacterium tuberculosis (M. tuberculosis), still accounts for 1.8 million global deaths annually [1,2]. It has been estimated that about one-third of the global population is latently infected with M. tuberculosis which reflects a big reservoir for developing new active cases [3]. In recent years, the rise in numbers of multidrug-resistant (MDR) and extensively drug-resistant (XDR) isolates of M. tuberculosis have seriously hampered the treatment of disease [4]. The prevalence of HIV/AIDS epidemic in addition to unwanted drug-drug interactions has further burdened the treatment of TB [5,6].

Source: International Journal of Antimicrobial Agents - September 26, 2018 Category: Drugs & Pharmacology Authors: Aehtesham Hussain, Muzafar Ahmad Rather, Zubair Shanib Bhat, Aasif Majeeda Mubashir Maqbool, Aabid Manzoor Shah, Mushtaq A Aga, Aiyatullah Shah, Saleem Mushtaq, Payare L Sangwan, Qazi Parvaiz Hassan, Zahoor Ahmad Source Type: research